4.7 Article

The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2

Journal

ANTIOXIDANTS
Volume 12, Issue 1, Pages -

Publisher

MDPI
DOI: 10.3390/antiox12010133

Keywords

obesity; adipocytic differentiation; reactive oxygen species (ROS); xanthine oxidoreductase (XOR); febuxostat; Nrf2; Keap1

Ask authors/readers for more resources

Xanthine oxidoreductase (XOR) is a rate-limiting enzyme in purine catabolism and a novel regulator of adipogenesis. The XOR inhibitor febuxostat alleviates adipose tissue mass increase in obese mouse models and disrupts adipocytic differentiation in vitro. Febuxostat suppresses ROS production, induces Nrf2 activation, and inhibits adipogenesis under oxidative conditions. These findings suggest that febuxostat may be a potential treatment for obesity associated with menopause or overeating.
Xanthine oxidoreductase (XOR) is a rate-limiting enzyme in purine catabolism that acts as a novel regulator of adipogenesis. In pathological states, xanthine oxidoreductase activity increases to produce excess reactive oxygen species (ROS). The nuclear factor erythroid 2-related factor 2 (Nrf2) is a critical inducer of antioxidants, which is bound and repressed by a kelch-like ECH-associated protein 1 (Keap1) in the cytoplasm. The Keap1-Nrf2 axis appears to be a major mechanism for robust inducible antioxidant defenses. Here, we demonstrate that febuxostat, a xanthine oxidase inhibitor, alleviates the increase in adipose tissue mass in obese mouse models with a high-fat diet or ovariectomy. Febuxostat disrupts in vitro adipocytic differentiation in adipogenic media. Adipocytes appeared at day 7 in absence or presence of febuxostat were 160.8 +/- 21.2 vs. 52.5 +/- 12.7 (p < 0.01) in 3T3-L1 cells, and 126.0 +/- 18.7 vs. 55.3 +/- 13.4 (p < 0.01) in 10T1/2 cells, respectively. Adipocyte differentiation was further enhanced by the addition of hydrogen peroxide, which was also suppressed by febuxostat. Interestingly, febuxostat, but not allopurinol (another xanthine oxidase inhibitor), rapidly induced the nuclear translocation of Nrf2 and facilitated the degradation of Keap1, similar to the electrophilic Nrf2 activator omaveloxolone. These results suggest that febuxostat alleviates adipogenesis under oxidative conditions, at least in part by suppressing ROS production and Nrf2 activation. Regulation of adipocytic differentiation by febuxostat is expected to inhibit obesity due to menopause or overeating.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available